{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:10:30Z","timestamp":1790939430026,"version":"4.1.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.11.017","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T09:59:17Z","timestamp":1264499957000},"page":"2349-2370","source":"Crossref","is-referenced-by-count":119,"special_numbering":"P2","title":["Current and emerging therapies for acute myeloid leukemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.11.017_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.11.017_bib3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: Epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2009.11.017_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1067\/mps.2002.121791","article-title":"Acute myelogenous leukemia","volume":"32","author":"Aquino","year":"2002","journal-title":"Curr Probl Pediatr Adolesc Health Care."},{"key":"10.1016\/j.clinthera.2009.11.017_bib6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1634\/theoncologist.2008-0100","article-title":"Current and emerging strategies for the management of acute myeloid leukemia in the elderly","volume":"13","author":"Laubach","year":"2008","journal-title":"Oncologist."},{"key":"10.1016\/j.clinthera.2009.11.017_bib7","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/cncr.23000","article-title":"Progress in the treatment of acute myeloid leukemia","volume":"110","author":"Ravandi","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2009.11.017_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation-2005.1.143","article-title":"New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents","author":"Tallman","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.11.017_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.12-S2-14","article-title":"Recent developments in acute myelogenous leukemia therapy","volume":"12","author":"King","year":"2007","journal-title":"Oncologist."},{"key":"10.1016\/j.clinthera.2009.11.017_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4065\/81.2.247","article-title":"Adult acute myeloid leukemia [published correction appears in Mayo Clin Proc. 2006;81:569]","volume":"81","author":"Jabbour","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.clinthera.2009.11.017_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia [published correction appears in Blood. 2005;106:2243]","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/asheducation-2003.1.82","article-title":"Acute myeloid leukemia and acute promyelocytic leukemia","author":"L\u00f6wenberg","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.clinthera.2009.11.017_bib13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","article-title":"Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia","volume":"77","author":"Berman","year":"1991","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","article-title":"Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia","volume":"79","author":"Wiernik","year":"1992","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib16","first-page":"177","article-title":"Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)","volume":"4","author":"Arlin","year":"1990","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.017_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute nonlymphocytic leukemia","volume":"75","author":"Bishop","year":"1990","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2141.2005.05745.x","article-title":"Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients [published correction appears in Br J Haematol. 2006;132: 804]","volume":"131","author":"Russo","year":"2005","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":". Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.017_bib20","series-title":"Blood (ASH Annual Meeting Abstracts)","first-page":"112","article-title":"Addition of cladribine to the standard daunorubicinecytarabine (DA 3+7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60 Y: A multicenter, randomized, phase III PALG AML 1\/2004 DAF\/DAC\/DA study in 673 patients","author":"Holowiecki","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.017_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.1998.00948.x","article-title":"A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia","volume":"103","year":"1998","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1042819021000035608","article-title":"Purine nucleoside analogues in the treatment of myeloid leukemias","volume":"44","author":"Robak","year":"2003","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clinthera.2009.11.017_bib23","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of highdose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib24","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standarddose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib25","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standarddose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group","volume":"93","author":"B\u00fcchner","year":"1999","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.21543","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials","volume":"107","author":"Kern","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2009.11.017_bib27","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.2005.04.5013","article-title":"Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia","volume":"24","author":"B\u00fcchner","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib28","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2003-10-3561","article-title":"Randomized comparison of double induction and timed-sequential induction to a \u201c3 + 7\u201d induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study","volume":"104","author":"Castaigne","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.beha.2007.11.004","article-title":"Consolidation therapy: What should be the standard of care?","volume":"21","author":"Rowe","year":"2008","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acutemyeloid leukemia in first remission","volume":"339","author":"Cassileth","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.11.017_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","article-title":"Guidelines on the management of acute myeloid leukaemia in adults","volume":"135","author":"Milligan","year":"2006","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.6004\/jnccn.2008.0076","article-title":"Optimizing therapy for acute myeloid leukemia","volume":"6","author":"Kohrt","year":"2008","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.clinthera.2009.11.017_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.11.017_bib34","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) (p13q22) or t(16;16)(p13;q22): Results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib36","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib37","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.leu.2401068","article-title":"Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: A randomized trial of the Finnish Leukemia Group","volume":"12","author":"Elonen","year":"1998","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.017_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(84)90424-0","article-title":"Acute myelogenous leukaemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival","volume":"1","author":"Sauter","year":"1984","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.11.017_bib39","first-page":"285","article-title":"Acute myeloid leukemia in adults: Is postconsolidation maintenance therapy necessary?","volume":"72","author":"B\u00fcchner","year":"2000","journal-title":"Int J Hematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib40","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1200\/JCO.2003.02.133","article-title":"6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group","volume":"21","author":"B\u00fcchner","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11864-007-0041-1","article-title":"Maintenance for acute myeloid leukemia revisited","volume":"8","author":"B\u00fcchner","year":"2007","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10428190290006053","article-title":"The search for optimal treatment in relapsed and refractory acute myeloid leukemia","volume":"43","author":"Robak","year":"2002","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clinthera.2009.11.017_bib43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOH.0b013e3282f463d2","article-title":"Novel strategies for relapsed and refractory acute myeloid leukemia","volume":"15","author":"Mato","year":"2008","journal-title":"Curr Opin Hematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib44","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/sj.leu.2401141","article-title":"Duration of first remission predicts remission rates and longterm survival in children with relapsed acute myelogenous leukemia","volume":"12","author":"Stahnke","year":"1998","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.017_bib45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.leu.2401668","article-title":"Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities","volume":"14","author":"Kern","year":"2000","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.017_bib46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10428190009148395","article-title":"Cyclophosphamide, ara-C and to-potecan (CAT) for patients with refractory or relapsed acute leukemia","volume":"36","author":"Cortes","year":"2000","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clinthera.2009.11.017_bib47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428190009113388","article-title":"Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia","volume":"39","author":"Ferr\u00e1","year":"2000","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clinthera.2009.11.017_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","article-title":"Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial","volume":"118","author":"Burnett","year":"2002","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157488706776876445","article-title":"Treatment of relapsed acute myeloid leukaemia","volume":"1","author":"Kell","year":"2006","journal-title":"Rev Recent Clin Trials."},{"key":"10.1016\/j.clinthera.2009.11.017_bib51","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2005-10-4202","article-title":"Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: Results of the MRC AML-HR randomized trial","volume":"107","author":"Milligan","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-0609.1990.tb00445.x","article-title":"High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukemia: A prospective randomized study","volume":"45","author":"Martiat","year":"1990","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2141.1992.tb06427.x","article-title":"The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: A Leukemia Intergroup study","volume":"82","author":"Larson","year":"1992","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.11.017_bib54","first-page":"1847","article-title":"A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia","volume":"8","author":"Vogler","year":"1994","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.017_bib55","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V83.8.2086.2086","article-title":"A double-blind controlled study of granulocyte colonystimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia","volume":"83","author":"Ohno","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0145-2126(99)00087-9","article-title":"A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study","volume":"23","author":"Karanes","year":"1999","journal-title":"Leuk Res."},{"key":"10.1016\/j.clinthera.2009.11.017_bib57","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.leu.2401474","article-title":"Granulocyte-macrophage colonystimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 Trial)","volume":"13","author":"Thomas","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2009.11.017_bib58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2141.2001.02785.x","article-title":"Comparison of \u2018sequential\u2019 versus \u2018standard\u2019 chemotherapy as re-induction treatment, with or without cyclosporine, in refractory\/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial","volume":"113","author":"Liu Yin","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib59","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","article-title":"Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leuke- mia: A Southwest Oncology Group study","volume":"98","author":"List","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib60","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","article-title":"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)","volume":"22","author":"Greenberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib61","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib62","article-title":"A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without Cloretazine\u00ae in patients with first relapse of acute myeloid leukemia (AML)","volume":"108","author":"Giles","year":"2006"},{"key":"10.1016\/j.clinthera.2009.11.017_bib63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","article-title":"Treatment of relapsed and refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2009.11.017_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/157488706775246102","article-title":"Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders","volume":"1","author":"Robak","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.clinthera.2009.11.017_bib65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002770050541","article-title":"Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML","volume":"78","author":"Steinmetz","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.2001.02551.x","article-title":"A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colonystimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess ofblasts in transformation","volume":"112","author":"Jackson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0145-2126(02)00003-6","article-title":"FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies","volume":"26","author":"de la Rubia","year":"2002","journal-title":"Leuk Res."},{"key":"10.1016\/j.clinthera.2009.11.017_bib68","first-page":"513","article-title":"High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2009.11.017_bib69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428190109057928","article-title":"Treatment of \u201cpoor risk\u201d acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): A single center study","volume":"40","author":"Carella","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2009.11.017_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","article-title":"A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia\u2014a report of the Polish Adult Leukemia Group (PALG)","volume":"71","author":"Wrzesie\u0144Ku\u015b","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib71","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-003-0624-2","article-title":"FLAG-IDA in the treatment of refractory\/relapsed acute myeloid leukemia: Single-center experience","volume":"82","author":"Pastore","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib72","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000055107","article-title":"Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia","volume":"24","author":"H\u00e4nel","year":"2001","journal-title":"Onkologie"},{"key":"10.1016\/j.clinthera.2009.11.017_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s002770050239","article-title":"FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia","volume":"73","author":"Huhmann","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-008-0571-z","article-title":"Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients","volume":"88","author":"Camera","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib75","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.11791","article-title":"Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia","volume":"98","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.11.017_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.beha.2007.11.009","article-title":"New approaches in acute myeloid leukemia","volume":"21","author":"Blum","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ctrv.2007.09.001","article-title":"Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia","volume":"34","author":"Stasi","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.clinthera.2009.11.017_bib78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.beha.2006.11.006","article-title":"Targeted agents in AML: Much more to do","volume":"20","author":"Stone","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib79","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib80","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14728220902787628","article-title":"Targeted therapy in acute myeloid leukaemia: Current status and future directions","volume":"18","author":"Stapnes","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2009.11.017_bib81","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1159\/000109956","article-title":"Gemtuzumab ozogamicin (Mylotarg) for the treatment of acute myeloid leukemiaongoing trials","volume":"30","author":"Gleissner","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.clinthera.2009.11.017_bib82","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","article-title":"Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia","volume":"26","author":"Chevallier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib83","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.leukres.2008.05.011","article-title":"Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years","volume":"32","author":"Candoni","year":"2008","journal-title":"Leuk Res."},{"key":"10.1016\/j.clinthera.2009.11.017_bib84","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1080\/10428190802451254","article-title":"Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: Results from a pilot trial","volume":"49","author":"Nand","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2009.11.017_bib85","doi-asserted-by":"crossref","first-page":"15091","DOI":"10.1073\/pnas.96.26.15091","article-title":"Engagement of p75\/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells","volume":"96","author":"Vitale","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2009.11.017_bib86","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V83.7.1760.1760","article-title":"A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity","volume":"83","author":"Caron","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib87","first-page":"1421","article-title":"Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia","volume":"4","author":"Caron","year":"1998","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.clinthera.2009.11.017_bib88","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.leu.2402803","article-title":"Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195","volume":"17","author":"Feldman","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2009.11.017_bib89","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/molecules14031183","article-title":"Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases","volume":"14","author":"Robak","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.clinthera.2009.11.017_bib90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MOH.0b013e3282f46e94","article-title":"Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia","volume":"15","author":"Faderl","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib91","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/138955706776876212","article-title":"Pharmacological and clinical studies on purine nucleoside analogs\u2014new anticancer agents","volume":"6","author":"Lech-Maranda","year":"2006","journal-title":"Mini Rev Med Chem."},{"key":"10.1016\/j.clinthera.2009.11.017_bib92","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.017_bib93","article-title":"A Phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy","volume":"104","author":"Burnett","year":"2004"},{"key":"10.1016\/j.clinthera.2009.11.017_bib94","article-title":"Effectiveness of clofarabine in elderly AML patients with adverse cytogenetics unfit for intensive chemotherapy","volume":"108","author":"Burnett","year":"2006"},{"key":"10.1016\/j.clinthera.2009.11.017_bib95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","article-title":"Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib96","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus lowdose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/14737140.2.3.261","article-title":"Troxacitabine-based therapy of refractory leukemia","volume":"2","author":"Giles","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clinthera.2009.11.017_bib98","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.2001.19.3.762","article-title":"Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia","volume":"19","author":"Giles","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib99","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1200\/JCO.20.3.656","article-title":"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia","volume":"20","author":"Giles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2006.06.6209","article-title":"Phase I\/II study of continuousinfusion troxacitabine in refractory acute myeloid leukemia","volume":"25","author":"Roboz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib101","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.2003.11.016","article-title":"Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia","volume":"21","author":"Giles","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib102","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.bjc.6603896","article-title":"Antiproliferative effects of sapacitabine (CYC682), a novel 2\u2032-deoxycytidine-derivative, in human cancer cells","volume":"97","author":"Serova","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2009.11.017_bib103","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3322\/caac.20003","article-title":"Novel agents on the horizon for cancer therapy","volume":"59","author":"Ma","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2009.11.017_bib104","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/CCO.0b013e328313699c","article-title":"Demethylating agents in myeloid malignancies","volume":"20","author":"Garcia-Manero","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2008.09.001","article-title":"Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly","volume":"35","author":"Kuendgen","year":"2009","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.clinthera.2009.11.017_bib106","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/1097-0142(197811)42:5<2111::AID-CNCR2820420505>3.0.CO;2-I","article-title":"5-Azacytidine in acute leukemia","volume":"42","author":"Saiki","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.11.017_bib107","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodys-plastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib108","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/cncr.22204","article-title":"Treatment of acute myelogenous leukemia with outpatient azacitidine","volume":"107","author":"Sudan","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.11.017_bib109","article-title":"Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML)","volume":"108","author":"Cashen","year":"2006"},{"key":"10.1016\/j.clinthera.2009.11.017_bib110","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.clinthera.2009.11.017_bib111","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib112","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib113","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2008.07099.x","article-title":"Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia","volume":"141","author":"Braun","year":"2008","journal-title":"Br J Haematol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.11.017_bib114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/107327480801504s05","article-title":"Future directions in myelodysplastic syndrome: Newer agents and the role of combination approaches","volume":"15","author":"Gore","year":"2008","journal-title":"Cancer Control"},{"key":"10.1016\/j.clinthera.2009.11.017_bib115","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1600-0609.2004.00336.x","article-title":"The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro","volume":"73","author":"Korycka","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib116","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib117","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poorrisk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib118","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","article-title":"A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib119","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/1078-0432.CCR-07-4743","article-title":"Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poorrisk features","volume":"14","author":"Karp","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib120","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2008-08-172726","article-title":"Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: A preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide","volume":"113","author":"Karp","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib121","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-008-0536-2","article-title":"Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: A phase II study","volume":"87","author":"Ravoet","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib122","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2008.156","article-title":"On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2009.11.017_bib123","first-page":"3033","article-title":"1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino) carbonylhydrazine(101M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity","volume":"61","author":"Finch","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib124","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.leukres.2009.01.025","article-title":"Effect ofcloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin","volume":"33","author":"Morris","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib125","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-03-0738","article-title":"A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia","volume":"10","author":"Giles","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib126","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1158\/1078-0432.CCR-05-1070","article-title":"Phase I study of cloretazine (VNP40101M), a novel sulfonyl-hydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia","volume":"11","author":"Giles","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2006.07.0961","article-title":"Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia","volume":"25","author":"Giles","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib128","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2006.02.019","article-title":"A phase II study of cloretazine (VNP40101M), a novel sulfonyl- hydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia","volume":"30","author":"Giles","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.11.017_bib130","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","article-title":"Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification?","volume":"109","author":"Mr\u00f3zek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib131","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib132","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.2006.06219.x","article-title":"Current therapeutic strategies for acute myeloid leukaemia","volume":"134","author":"Kolitz","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib133","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1182\/blood-2004-03-1034","article-title":"Pediatric AML primary samples with FLT3\/ITD mutations are preferentially killed by FLT3 inhibition","volume":"104","author":"Brown","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib134","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib135","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib136","first-page":"46","article-title":"Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications","volume":"11","author":"Cheng","year":"2008","journal-title":"IDrugs"},{"key":"10.1016\/j.clinthera.2009.11.017_bib137","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib138","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2006-04-015487","article-title":"The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: The induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib139","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a smallmolecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib140","article-title":"Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML","volume":"106","author":"Stone","year":"2005"},{"key":"10.1016\/j.clinthera.2009.11.017_bib141","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood-2004-12-4633","article-title":"Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction","volume":"108","author":"Wilson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib142","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V88.4.1198.bloodjournal8841198","article-title":"Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study","volume":"88","author":"Solary","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib143","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.leukres.2004.03.001","article-title":"Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the DutchBelgian Haemato-Oncology Working Group for adults","volume":"28","author":"Daenen","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib144","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232","article-title":"Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720","volume":"100","author":"Baer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib145","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/blood-2005-04-1395","article-title":"The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis","volume":"106","author":"van der Holt","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib146","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the LRF AML 14 trial","volume":"145","author":"Burnett","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib147","first-page":"782","article-title":"Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine","volume":"89","author":"Gerrard","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2009.11.017_bib148","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib149","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1705739","article-title":"Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant","volume":"40","author":"Vicente","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2009.11.017_bib150","first-page":"111","article-title":"Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia","volume":"18","author":"Gorin","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2009.11.017_bib151","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","article-title":"A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome","volume":"9","author":"Fung","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2009.11.017_bib152","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1365-2141.1998.896hm3674.x","article-title":"The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: An analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA","volume":"102","author":"Keating","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib153","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group\/Eastern Cooperative Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib154","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years old with acute myeloid leukemia (AML) in first complete remission (CR1): An intention to treat analysis of the EORTC\/ GIMEMAAML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib155","first-page":"2978","article-title":"Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia","volume":"90","author":"Harousseau","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib156","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib157","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib158","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00001622-200203000-00003","article-title":"Autologous stem cell transplantation for adult acute leukemia","volume":"14","author":"Gorin","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib159","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.bmt.1702519","article-title":"Unrelated donor marrow trans- plantation for acute myeloid leu- kemia: An update of the Seattle experience","volume":"26","author":"Sierra","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2009.11.017_bib160","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa041469","article-title":"Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia","volume":"351","author":"Rocha","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.11.017_bib161","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","article-title":"Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors","volume":"24","author":"Hegenbart","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.017_bib162","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2009.11.017_bib163","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.017_bib164","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.leukres.2003.10.029","article-title":"Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission","volume":"28","author":"Levi","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2009.11.017_bib165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","article-title":"Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia","volume":"332","author":"Zittoun","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.11.017_bib166","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminhematol.2007.08.002","article-title":"Acute myeloid leukemia and the position of autologous stem cell transplantation","volume":"44","author":"Breems","year":"2007","journal-title":"Semin Hematol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180900407X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180900407X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T01:23:37Z","timestamp":1590542617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180900407X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":164,"alternative-id":["S014929180900407X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}